Tegavivint for relapsed or hard-to-treat lymphoma patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older with relapsed or refractory large B-cell lymphoma or a related transformation (as described by the study).
- Your lymphoma tissue test must match specific “high MYC and BCL2” patterns or certain gene rearrangements, or it must be a high-grade double/triple-hit type.
- You’ve already tried at least two prior body-wide (systemic) treatments.
- You can’t safely get or chose not to get stem cell transplant (from your own or a donor) or CAR T-cell therapy (these are allowed only if done at least 3 months ago).
- The lymphoma must be measurable on a PET scan, and you must have enough blood counts (neutrophils and platelets) and adequate liver/kidney function.
- You must be able to attend study visits and sign written informed consent, and your daily function score must be 0–2 (not fully bedridden).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.